Activación de los receptores de vitamina D en la optimización del hiperparatiroidismo secundario en diálisis

Herrero, José A; López-Gómez, Juan M; Maduell, Francisco; Martín-de Francisco, Ángel L; Martín-Malo, Alejandro; Martínez-Castelao, Alberto; Navarro-González, Juan F; Pérez-Fontán, Miguel; Pérez, Jesús; Selgas, Rafael; Solozabal, Carlos.
Nefrología (Madr.) ; 33(4): 571-584, jul.-ago. 2013. ilus, tab
Artículo en Español | IBECS (España) | ID: ibc-117275

Documentos relacionados

  1. [Paricalcitol - a selective vitamin D receptor activator for secondary hyperparathyroidism in patients with chronic kidney disease].
  2. Effects of evocalcet on parathyroid calcium-sensing receptor and vitamin D receptor expression in uremic rats.
  3. Pharmacogenetic role of vitamin D-binding protein and vitamin D receptor polymorphisms in the treatment response of dialysis patients with secondary hyperparathyroidism.
  4. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.
  5. Correlation of vitamin D receptor genotypes, specific IgE levels and other variables with asthma control in children.
  6. Electrocardiographic, biochemical, and scintigraphic evidence for the cardioprotective effect of paricalcitol and vitamin D3 on doxorubicin-induced acute cardiotoxicity in rats.
  7. [Gene polymorphism of the vitamin D receptor, vitamin D-binding protein and calcium-sensing receptor in respect of calcium-phosphate disturbances in chronic dialysis patients].
  8. Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.
  9. Vitamin D Receptor Agonists for Patients Undergoing Hemodialysis.
  10. Methylation of the Vitamin D Receptor Gene in Human Disorders.